Aspen of South Africa hopes to generate a profit by using GLP-1 medications and insulin
The new tab manufacturing business at Aspen Pharmacare (APNJ.J) wants to make more money by 2027 by commercializing an insulin deal and making GLP-1 drugs. This is because the end of a major contract caused the company to lose 1.1 billion rand ($63 million) for the whole year.
Aspen said on Wednesday that the year ending June 30 had an after-tax loss of 4.1 billion rand due to the loss of assets. This was compared to a profit of 4.4 billion rand the previous year.
In terms of steady currency, the group’s income went up by 1% to 43 billion rand.
Aspen announced in April that it was in a disagreement with a customer over a contract to make messenger ribonucleic acid (mRNA) products, like vaccines, using fake strands of genetic code to tell cells to make certain proteins. The specifics of the dispute are being kept secret.
The company said that the loss of the contract was the main reason why manufacturing sales dropped 21% to 11.1 billion rand and normalized earnings before interest, taxes, depreciation and amortization (EBITDA) dropped 62% to 668 million rand.
Aspen is moving toward commercialization and wants to make up for missed manufacturing capacity by signing a contract for insulin in South Africa. The business thought it would make around 300 million rand in fiscal year 2026 and over 1 billion rand in fiscal year 2027.
Aspen wants to cut costs, so in 2025 it plans to reorganize its factories in France and South Africa that make sterile drugs that don’t contain any living organisms.
For its manufacturing business as a whole, Aspen is betting on making vaccines for kids for the Serum Institute of India, which will start selling them in 2026, and adding GLP-1 drugs to both sites to treat obesity and diabetes.
Stephen Saad, CEO of the group, told Reuters, “We think those volumes will give us some upside.”
Commercial pharmaceuticals sales went up 5%, and normalized EBITDA growth was 1%. This was due to growth in injectables, over-the-counter meds, and prescriptions, which all brought in more money on their own. The launch of the diabetes drug Mounjaro in South Africa, which Aspen sells for Eli Lilly, brought in even more money.
